Intercept Pharmaceuticals Director Unloads $23,536,563 in Stock (ICPT)
Intercept Pharmaceuticals (NASDAQ:ICPT) Director Orbimed Advisors Llc sold 376,585 shares of Intercept Pharmaceuticals stock on the open market in a transaction that occurred on Tuesday, October 15th. The stock was sold at an average price of $62.50, for a total value of $23,536,562.50. The sale was disclosed in a filing with the SEC, which is available at this link.
A number of analysts have recently weighed in on ICPT shares. Analysts at Oppenheimer raised their price target on shares of Intercept Pharmaceuticals from $64.00 to $94.00 in a research note to investors on Tuesday, October 1st. They now have an “outperform” rating on the stock. Separately, analysts at BMO Capital Markets raised their price target on shares of Intercept Pharmaceuticals from $62.00 to $107.00 in a research note to investors on Friday, September 20th. They now have an “outperform” rating on the stock. Finally, analysts at BMO Capital Markets reiterated an “outperform” rating on shares of Intercept Pharmaceuticals in a research note to investors on Wednesday, August 14th. They now have a $62.00 price target on the stock, up previously from $44.00. One analyst has rated the stock with a sell rating and eight have issued a buy rating to the stock. The stock currently has a consensus rating of “Buy” and a consensus price target of $66.67.
Intercept Pharmaceuticals (NASDAQ:ICPT) traded down 0.42% on Thursday, hitting $59.89. 117,242 shares of the company’s stock traded hands. Intercept Pharmaceuticals has a 52-week low of $17.96 and a 52-week high of $77.53. The stock has a 50-day moving average of $58.14 and a 200-day moving average of $43.77. The company’s market cap is $1.149 billion.
Intercept Pharmaceuticals (NASDAQ:ICPT) last announced its earnings results on Tuesday, August 13th. The company reported ($0.79) EPS for the quarter, missing the Thomson Reuters consensus estimate of ($0.51) by $0.28. The company had revenue of $0.41 million for the quarter, compared to the consensus estimate of $0.40 million. On average, analysts predict that Intercept Pharmaceuticals will post $-2.43 earnings per share for the current fiscal year.
Intercept Pharmaceuticals, Inc is a biopharmaceutical company focused on the development and commercialization of therapeutics to treat chronic liver disease.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.